KYTX vs LBRX

Kyverna Therapeutics, Inc. vs LB Pharmaceuticals Inc — Valuation Comparison 2026

KYTX

Biotechnology
Kyverna Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
18
SAFE
Price
$8.65
Last close
Models
7/13
Active
VS

LBRX

Biotechnology
LB Pharmaceuticals Inc
Quality
4.6
out of 10
Value Trap
Price
$27.53
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType KYTX Fair ValueKYTX Upside LBRX Fair ValueLBRX Upside
Bayesian DCF Intrinsic $2.40 -72.3% $11.21 -59.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $2.70 -68.8% $9.44 -65.7%
Dynamic NAV Asset-Based $3.58 -58.6% $8.72 -68.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KYTX vs LBRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KYTX vs LBRX — Which Stock Is More Undervalued?

LBRX scores higher with a 4.6/10 quality rating vs KYTX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kyverna Therapeutics, Inc. (KYTX) and LB Pharmaceuticals Inc (LBRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KYTX currently trades at $8.65 with a QOC of 4.2/10, while LBRX trades at $27.53 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).